Pharmaceuticals, Biotechnology and Life Sciences
International Diabetes Federation (IDF) and Eli Lilly have come together for the second phase of the Bringing Research in Diabetes to Global Environments and Systems programme (BRIDGES 2), reaffirming their commitment to helping people with diabetes effectively manage their condition.
The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.
Johnson & Johnson has announced that, with today’s receipt of approval of the proposed acquisition of Actelion from the European Commission (EC), all regulatory approvals required to complete the transaction have been received.
Vertex Pharmaceuticals has appointed Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors.
Astellas Pharma and Pfizer have amended the protocol for the registrational PROSPER trial to test the efficacy and safety of Xtandi in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).
The programs assist injured veterans with mental health, physical health and wellness, career and benefits counseling, connecting warriors with one another and their communities, and long-term care for the most seriously wounded.
A study recently published showed that functional connectivity magnetic resonance imaging (fcMRI) may predict which high-risk, 6-month old infants will develop autism spectrum disorder by age 2 years.
Lyfebulb and Novo Nordisk have join again to support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes – and ultimately our societies.
Allergan’s wholly-owned subsidiary, Allergan Sales LLC has acquired Keller Medical, a privately held medical device company and developer of the Keller Funnel.
AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.